Quantitative determination method for heparan sulfate and diagnostic method using the same
AssigneeSeikagaku Kogyo Kabushiki Kaisha
InventorsShuichi Miyaura, Sawako Takeshita, Takeshi Ishimaru
Life of this patent
Estimating the term…
Abstract
The present invention relates to a quantitative determination method for heparan sulfate in body fluid specimens of various chronic diseases, in urine samples of diabetic nephropathy and for diagnosing hepatic diseases and rheumatoid arthritis in blood specimens. And also this method provides a diagnostic tool for judging the condition of diabetic nephropathy, hepatic diseases and rheumatoid arthritis by determination of changes by use of aforementioned quantitative determination of heparan sulfate.
Claims20
A method for quantitatively determining heparan sulfate contained in a specimen solution, which comprises the steps of:
- (a) contacting the specimen solution with an anti-heparan sulfate antibody immobilized on a solid phase, wherein said anti-heparan sulfate antibody exhibits no cross-reactivity with hyaluronic acid;
- (b) subjecting heparan sulfate contained in the specimen solution to antigen-antibody reaction with the anti-heparan sulfate antibody on the solid phase to form an antigen-antibody complex;
- (c) labeling the antigen-antibody complex with a labeling substance;
- (d) removing residues other than the labeled antigen-antibody complex from the solid phase;
- (e) detecting the labeling substance as an index of a quantity of the labeled antigen-antibody complex on the solid phase;
- and
- (f) calculating the quantity of heparan sulfate contained in the specimen solution based on a calibration curve obtained using a standard solution with the labeling substance.
A method for quantitatively determining heparan sulfate contained in a specimen solution, which comprises the steps of:
- a) contacting a specimen solution with biotin-labeled heparan sulfate on a microplate on which an anti-heparan sulfate antibody exhibiting specificity for at least an antigenic determinant of glucosamine residue with an N-sulfate group in heparan sulfate is attached, and causing a competitive antigen-antibody reaction between said biotin-labeled heparan sulfate and said heparan sulfate with respect to said anti-heparan sulfate antibody, said anti-heparan sulfate antibody exhibiting no cross reactivity with hyaluronic acid;
- b) binding avidin labeled with peroxidase to said biotin-labeled heparan sulfate attached to said anti-heparan sulfate antibody on the microplate;
- and
- c) measuring activity of said peroxidase.
A method for quantitatively determining heparan sulfate contained in a specimen solution, which comprises the steps of:
- (a) contacting the specimen solution with a solid phase on which heparan sulfate is immobilized;
- (b) adding an anti-heparan sulfate antibody onto the solid phase, wherein said anti-heparan sulfate antibody exhibits no cross-reactivity with hyaluronic acid;
- (c) subjecting heparan sulfate contained in the specimen solution and the immobilized heparan sulfate to antigen-antibody reaction with the anti-heparan sulfate antibody to form an antigen-antibody complex;
- (d) labeling the antigen-antibody complex with a labeling substance;
- (e) removing from the solid phase, residues other than the labeled antigen-antibody complex immobilized on the solid phase;
- (f) detecting the labeling substance as an index of a quantity of the labeled antigen-antibody complex on the solid phase;
- and
- (g) calculating the quantity of heparan sulfate contained in the specimen solution based on a calibration curve obtained using a standard solution with the labeling substance.
A method for quantitatively determining heparan sulfate contained in a specimen solution, which comprises the steps of:
- (a) contacting the specimen solution with a microparticulate solid phase on which heparan sulfate is immobilized;
- (b) adding an anti-heparan sulfate antibody into the specimen solution, wherein said anti-heparan sulfate antibody exhibits no cross-reactivity with hyaluronic acid;
- (c) subjecting heparan sulfate contained in the specimen solution and the immobilized heparan sulfate to competitive antigen-antibody reaction with the anti-heparan sulfate antibody to form aggregates of the microparticulates via antigen-antibody complexes;
- (d) removing residues other than the aggregates from the solid phase;
- (e) detecting the degree of aggregation of the microparticulates as an index of a quantity of the antigen-antibody complex formed on the microparticulates;
- and
- (f) calculating the quantity of heparan sulfate contained in the specimen solution based on a calibration curve obtained using a standard solution containing a known quantity of heparan sulfate in place of the specimen solution.
A method for diagnosing a progressing stage of incipiental diabetic nephropathy or diabetic nephropathy, comprising the steps of:
- subjecting heparan sulfate contained in a urine specimen to antigen-antibody reaction with an anti-heparan sulfate antibody;
- and quantitatively detecting the presence of heparan sulfate in the urine specimen reacted with the anti-heparan sulfate antibody.
Dependencies are inferred from the claim text.